Director Pamela Esposito sells entire 27,563-share position in KYMR for $2.3M across 4 transactions at $81.56–$84.07
Director Pamela Esposito liquidated her entire shareholding via 4 separate sales totaling 27,563 shares for $2,264,480.28, executed at prices ranging from $81.56 to $84.07 on 2025-12-17. This represents a complete exit from equity ownership in Kymera Therapeutics. The timing merits context: the stock trades $82.07 currently, near the transaction prices, and is down -13.0% from its 52-week high of $94.30, despite a strong 30-day and 90-day performance (+28.0% and +60.4% respectively). Against this backdrop, the company faces material headwinds—revenue $2.8M in the latest quarter with annual revenue growth of -40.1%, and a net loss of $82.2M over its most recent full fiscal year. The director's complete exit occurs in a context of deteriorating financial performance and pullback from 52-week highs, warranting investor scrutiny of insider confidence levels.